Retrieved from Liu, L., Chen, J., Wang, L., et al
Trials to date have focused on weight and metabolic outcomes, with lean mass reduction typically reported as a secondary endpoint and without standardized functional measures
Losing a significant amount of weight is an incredible accomplishment
Until approval occurs, compounded GLP-1 remains the most accessible lower-cost option for patients without coverage or with high deductibles
Because fat cannot be efficiently oxidized for energy without adequate carnitine-mediated transport, research has examined supplemental carnitine's role in exercise metabolism, mitochondrial efficiency, and recovery from metabolic stress, as well as its secondary antioxidant properties within the mitochondrial matrix
A research team led by Aparna Kamat, chair of gynecologic oncology at Houston Methodist Hospital in the United States, reported on the 7th in the international journal Annals of Oncology that they had identified an association between the use of GLP-1 class obesity drugs and cancer incidence in patients with obesity who do not have diabetes